CuraTeQ Biologics (Malta) Limited
4 products tracked · names used in filings: CuraTeQ Biologics (Malta) Limited
Upcoming milestones
Mon 21 Dec 2026🇪🇺 Expected EC decisionestimatein 37 days
Neuzafy (filgrastim): expected EC decision
Estimated as CHMP opinion (2026-10-15) + 67 days, the standard Commission decision period. Not an official date. · CuraTeQ Biologics (Malta) Limited · source
Recent milestones
Thu 15 Oct 2026🇪🇺 CHMP positive opinion
Neuzafy (filgrastim): CHMP positive opinion
CuraTeQ Biologics (Malta) Limited; Biosimilar · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Neuzafy filgrastim | Opinion | |
| 🇪🇺 | Dazublys trastuzumab | Authorised | 2025-06-30 |
| 🇪🇺 | Dyrupeg pegfilgrastim | Authorised | 2025-03-28 |
| 🇪🇺 | Zefylti filgrastim | Authorised | 2025-02-12 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.